Senotherapy

Senotherapeutics refers to therapeutic agents/strategies that specifically target cellular senescence.¹ Senotherapeutics include emerging senolytic/senoptotic small molecules that specifically induce cell death in senescent cells ² and agents that inhibit the pro-inflammatory senescent secretome.³ Senescent cells can be targeted for immune clearance, but an ageing immune system likely impairs senescent cell clearance leading to their accumulation.⁴ Therefore, agents which can enhance immune clearance of senescent cells can also be considered as senotherapeutic.

References

Childs et al. (2015). Cellular senescence in aging and age-related disease: from mechanisms to therapy Nature Medicine {{doi:10.1038/nm.4000}}
Chang J., Wang Y.,Shao L. et al., & Zhou D. (2015). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine doi:10.1038/nm.4010
Xu et al. (2015). JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age PNAS {{doi: 10.1073/pnas.1515386112}}
Burton and Faragher (2015). Cellular senescence: from growth arrest to immunogenic conversion AGE {{doi:10.1007/s11357-015-9764-2}}

[1] Childs et al. (2015). Cellular senescence in aging and age-related disease: from mechanisms to therapy Nature Medicine {{doi:10.1038/nm.4000}}

[2] Chang J., Wang Y.,Shao L. et al., & Zhou D. (2015). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine doi:10.1038/nm.4010

[3] Xu et al. (2015). JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age PNAS {{doi: 10.1073/pnas.1515386112}}

[4] Burton and Faragher (2015). Cellular senescence: from growth arrest to immunogenic conversion AGE {{doi:10.1007/s11357-015-9764-2}}

1

2

3

4